Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 920 patients (estimated)
- Sponsors
- Hoffmann-La Roche
- Tags
- Pan-RAF Kinase Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1714
- NCT Identifier
- NCT04589845
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.